RepligenRGEN +9.56%83 FCF Margin % is 12.02% as of Mar. 2026, which is 23% above its 10-year median of 9.78. GuruFocus rates RGEN with a GF Score™ of 83/100 and a GF Value™ of $175.89 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Repligen ranks better than 82.09% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Repligen's Free Cash Flow for the
three
months ended in Mar. 2026 was $23.3 Mil. Repligen's Revenue for the
three
months ended in Mar. 2026 was $194.3 Mil. Therefore, Repligen's FCF Margin % for the quarter that ended in Mar. 2026 was 12.02%.
The historical rank and industry rank for Repligen's FCF Margin % or its related term are showing as below:
RGEN'
s FCF Margin % Range Over the Past 10 Years
Min: 3.06 Med: 9.78 Max: 22.46
Current: 13.68
During the past 13 years, the highest FCF Margin % of Repligen was 22.46%. The lowest was 3.06%. And the median was 9.78%.
RGEN's FCF Margin % is ranked better than 82.09% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs RGEN: 13.68
Repligen FCF Margin % Related Terms
Repligen FCF Margin % Historical Data
* Premium members only.
The historical data trend for Repligen's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Repligen's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repligen FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Repligen's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Repligen's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Repligen (RGEN) has a FCF Margin % of 12.02% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Repligen and its competitors. This is 23% above median its historical median of 9.78. Over the past decade, Repligen's FCF Margin % has ranged from 3.06 to 22.46. According to the industry distribution chart, Repligen ranks #146 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 17.9%.
Is Repligen's FCF Margin % too high?
Repligen's current FCF Margin % of 12.02% is 23% above median its 10-year median of 9.78. Over the past 10 years, this metric has ranged from a low of 3.06 to a high of 22.46. Based on the distribution chart, Repligen ranks #146 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Repligen has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's FCF Margin % compare to ATR and AVTR?
According to the Medical Devices & Instruments industry distribution chart, Repligen ranks #146 out of 815 companies for FCF Margin %. This places Repligen in the top 18% of its industry — outperforming the majority of peers. Historically, Repligen's own FCF Margin % has ranged from 3.06 to 22.46 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Repligen and its competitors. Repligen's current FCF Margin % is 12.02%, which is 23% above median its own 10-year median of 9.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $175.89, compared to a current price of $138.47 — trading 21.3% below its estimated fair value. The current FCF Margin % is 12.02%, which is 23% above median its 10-year median of 9.78. Repligen's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Repligen (RGEN), the current FCF Margin % is 12.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Repligen (RGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Repligen stock appears to be undervalued.
The current stock price of $138.47 is trading 21.3% below its estimated GF Value™ of $175.89.
GuruFocus considers Repligen to be Modestly Undervalued.
Key valuation signals for RGEN:
FCF Margin %: 12.02% (23% above median its 10-year median of 9.78)
GF Value™: $175.89 vs. price of $138.47 (21.3% below fair value)
No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
83GF Score
Get the complete analysis for RGEN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEN has been successfully added to your 
